Close Menu

aneuploidy

Last Week's Clinical Sequencing Papers of Note

Using a sequencing method and proprietary algorithm based on technology licensed from Stephen Quake at Stanford University, the researchers correctly identified all trisomy 21 and trisomy 18 cases.

In the amended deal, a milestone payment for which Fluidigm may be eligible has been increased, and the time period during which Novartis may license the technology being developed was also modified.

A recent study adds to a growing body of evidence that Genomed's Aneufast QF-PCR test has the potential to be routinely used for prenatal aneuploidy detection in North America. However, in the US the test first needs 510(k) clearance, which depends on whether the Applied Biosystems genetic analyzer on which Aneufast is performed also receives diagnostic approval.

The company has filed a registration statement with the SEC for a proposed initial public offering worth up to $86.3 million, reviving plans for an IPO the company scrapped in September 2008 due to rapidly deteriorating economic conditions.

At the UBS Global Life Sciences Conference this week, Ron Lindsay, Sequenom's senior vice president of R&D, said that the company recently completed a technical study of its test and will soon embark on a validation study.

Pages

Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.

US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.

The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.

In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.